08:00 , Dec 11, 2006 |  BioCentury  |  Strategy

The fork in the road

Access to the next generation of antibody-like assets became more difficult last Friday when GlaxoSmithKline plc unveiled a £230 million ($455 million) bid for Domantis Inc., the developer of domain antibodies (dAbs), the smallest functional...
03:41 , Dec 13, 2005 |  BC Extra  |  Financial News

Domantis raises $29 million

Domantis (Cambridge, U.K.) raised $29 million in an extension of a series B round from new investors Novo Nordisk (NVO) and Mitsubishi's MC Life Science Ventures, as well as existing investors 3i; Gray Ghost; Albany...
08:00 , Dec 12, 2005 |  BioCentury  |  Strategy

Westward Ho

While Europe seems to have few problems creating new biotech companies, it finds it difficult hanging onto those that are most ambitious, as Immuno-Designed Molecules S.A. , Microscience Ltd. and Hormos Medical Corp. all have...
00:41 , Jul 14, 2005 |  BC Extra  |  Financial News

Xention raises L11 million

Xention (Cambridge, U.K.) raised L11 million ($19.1 million) in a series B round led by new investor ABN AMRO. Credit Agricole joined existing investors MVM; Quester; BTG; Isis Equity; Albany Ventures; and Enterprise VCT in...
07:00 , May 24, 2004 |  BioCentury  |  Finance

Top European B rounds

Top European B rounds...
07:00 , May 17, 2004 |  BioCentury  |  Finance

U.S. investment in Europe

U.S. investment in Europe...
08:00 , Mar 1, 2004 |  BioCentury  |  Finance

Ebb & Flow

Even though the market had expected approval of...
08:00 , Feb 23, 2004 |  BC Extra  |  Financial News

Domantis raises L17.5 million

Domantis (Cambridge, U.K.) raised L17.5 million ($33 million) in a series B round led by 3i. Other investors included Gray Ghost; Albany Ventures; MVM; and Peptech . Nigel Pitchford, associate director of 3i, joined Domantis'...